adempas
bayer ag - riociguat - hypertensio, keuhkokuume - keuhkoverenpainetaudin verenpainelääkkeet - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. teho on osoitettu in pah väestöön, mukaan lukien etiologia idiopaattinen tai periytyviä pah-yhdisteiden tai pah-yhdisteiden liittyy sidekudoksen sairaus. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.
magnesiamaito 82.5 mg/ml oraalisuspensio
orion corporation - magnesium hydroxide pasta - oraalisuspensio - 82.5 mg/ml - magnesiumhydroksidi
ranisan 150 mg tabletti, kalvopäällysteinen
sandoz a/s sandoz a/s - ranitidini hydrochloridum - tabletti, kalvopäällysteinen - 150 mg - ranitidiini
tagrisso
astrazeneca ab - osimertinib mesilate - karsinooma, ei-pienisoluinen keuhko - muut antineoplastiset aineet, proteiinikinaasin estäjät - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.
marevan 3 mg tabletti
orion corporation - warfarin sodium - tabletti - 3 mg - varfariini
marevan forte 5 mg tabletti
orion corporation - warfarin sodium - tabletti - 5 mg - varfariini
novantrone 2 mg/ml infuusiokonsentraatti, liuosta varten
meda oy - mitoxantroni hydrochloridum - infuusiokonsentraatti, liuosta varten - 2 mg/ml - mitoksantroni
sporanox 100 mg kapseli, kova
janssen-cilag oy - itraconazole - kapseli, kova - 100 mg - itrakonatsoli
sporanox 10 mg/ml oraaliliuos
janssen-cilag oy - itraconazole - oraaliliuos - 10 mg/ml - itrakonatsoli
mitoxantron ebewe 2 mg/ml infuusiokonsentraatti, liuosta varten
ebewe pharma ges.m.b.h. nfg.kg - mitoxantrone hydrochloride - infuusiokonsentraatti, liuosta varten - 2 mg/ml - mitoksantroni